Photo: Laura Hasani
The director of the Center for Blood Transfusion, Bukurie Zhubi, in an interview for Ekonomia Online said that after the decrease in the number of people infected with COVID-19, the interest for blood plasma has also decreased.
Blood plasma, she explained, has an impact as a supportive therapy in patients with COVID-19. She explained that this method of plasma treatment has been applied continuously for many diseases within the Infectious Diseases Clinic of UCCK.
“Interest in covalent plasma is still present. We have amassed a considerable amount. Their use has been very topical in the stage when we had COVID-19 disease. Now with the decrease in the number of cases with COVID-19 there is also a decrease in the use of covalent plasma.
“For covalent plasma efficacy, reports indicate that it has an effect as supportive therapy in patients with COVID-19,” she added.
This type of treatment is done by taking blood plasma from patients cured of coronavirus, as their blood has antibodies that fight the virus.
Antibody transfusion creates what is known as “passive immunity” in those affected by COVID-19.
Health institutions, through a guide, have started treating coronavirus-infected patients with convalescent plasma as supportive therapy during February.